Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (11744)	10/15/2018 7:33:41 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 12215

Volume dries up with overhang intact. Oh joy. They say that the death and life threatening events occurred in the last cohorts of each trial. I'm taking that at face value and assuming that it means "by design". Sure would be helpful to know if the actual dose was the same for each of the "last" cohorts. Anybody gotten that far or know how to find the doses? Have not yet looked through old posters. edit: when the neuro issue hit car-t at its hardest, many were saying that bispecifics would be fine tuned to have the efficacy, but that toxicities could be more readily controlled. But when you hit a hard and fast wall like that which may have been hit in the combo of these two trials? Might be good to drop down and expand more than one cohort before moving on to phase II?